Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
10.31
+0.20 (1.98%)
Dec 20, 2024, 4:00 PM EST - Market closed
Avadel Pharmaceuticals Employees
Avadel Pharmaceuticals had 154 employees as of December 31, 2023. The number of employees increased by 113 or 275.61% compared to the previous year.
Employees
154
Change (1Y)
113
Growth (1Y)
275.61%
Revenue / Employee
$897,143
Profits / Employee
-$471,266
Market Cap
993.49M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Brookdale Senior Living | 36,000 |
Owens & Minor | 22,200 |
OPKO Health | 3,930 |
Vir Biotechnology | 587 |
Bicycle Therapeutics | 284 |
Zymeworks | 278 |
Collegium Pharmaceutical | 197 |
AVDL News
- 5 weeks ago - Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation - GlobeNewsWire
- 2 months ago - US FDA expands approval for Avadel's sleep disorder drug - Reuters
- 2 months ago - Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy - GlobeNewsWire
- 3 months ago - Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On - Seeking Alpha
- 3 months ago - Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII) - GlobeNewsWire
- 4 months ago - Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire